This website uses cookies. By using the site you are agreeing to our Privacy Policy.

HOME >> Investor Relations >> Top Message >> Message Archive (October 30, 2015)


To Our Investors

One year has passed since the enforcement of the Pharmaceutical and Medical Device Act and Act on the Safety of Regenerative Medicine, and we are now seeing greater enthusiasm surrounding regenerative medicine. I will report below the recent situation of Japan Tissue Engineering (J-TEC).

Gamagori, a city of regenerative medicine

J-TEC is headquartered in Gamagori City, Aichi Prefecture. Gamagori is a small city with a population of approximately 80,000 people, but despite its size activities are being carried out that makes Gamagori stand out as “the city of regenerative medicine.” For instance, starting this fiscal year, the Committee for the Advancement of the Commercialization of Regenerative Medicine in Gamagori was organized with the Mayor as chairman. In August, approximately 100 people from universities, industries and the government (mainly from industries) involved in regenerative medicine gathered in Gamagori, where the Gamagori Summit was held to have honest and open discussion with an aim towards the commercialization and practical application of regenerative medicine. The Gamagori Summit Declaration was adopted as the compilation of discussions spanning over two days.

Gamagori Summit, Gamagori City website (in Japanese):

Meanwhile, in relation to the Act on the Safety of Regenerative Medicine enforced in November last year, Gamagori City Hospital was certified as a Certified Special Committee for Regenerative Medicine in July this year, and it is reviewing plans provided on regenerative medicine and the like submitted by various medical care providers. Furthermore, J-TEC acquired authorization as a Manufacturer of Special Processed Cells in October, thereby preparing an environment to be entrusted with cell culturing from medical care providers and the like.

A scheme is taking shape, whereby Gamagori is linked with regenerative medicine, and Gamagori is linked with J-TEC. We will further take action to bring about the day when Gamagori becomes famous among overseas affiliates as well.

Events leading up to the provision of JACE for burn patients in Taiwan

J-TEC has provided the autologous cultured epidermis “JACE” for free to patients who were injured in the dust explosion accident in Formosa Fun Coast in Taiwan on June 27 of this year. When about two weeks passed after the accident, J-TEC received a request to provide JACE by the Taiwan FDA. Medical cooperation has already been provided from around the world in various ways, but this was a request to provide JACE for patients in especially serious condition. Why did the Taiwan FDA make the request to J-TEC instead of others? Although it was coincidental, there have been recommendations for JACE to the Taiwan FDA from two different routes, including government officials and the academia, that have known J-TEC well. Through the accumulation of treatment results over eight years since 2007, when J-TEC obtained manufacturing and sales approval for JACE in Japan, the existence of JACE has also become recognized overseas.

J-TEC’s corporate philosophy starts with a line that reads, “J-TEC intends to become necessary to society through developing the regenerative medicine industry.” I am delighted to see that JACE has become necessary to society and that it could contribute to international emergency medical treatment. J-TEC has received a letter of appreciation from the Legislative Yuan (i.e. legislature of Taiwan). At the same time, a letter of appreciation was sent to the developer, Dr. Howard Green (Emeritus Professor, Harvard Medical School).

letter of appreciation

I sincerely wish for the smooth recovery not only of the five patients who underwent the JACE transplant surgery but also of all patients injured in the recent accident, and pray that their lives will return to normal.

October 30, 2015
Yosuke Ozawa
President & CEO
Japan Tissue Engineering Co., Ltd.